Evaluation of changes in prostate specific antigen in clinically localized prostate cancer managed without initial therapy

Journal of Urology

Volumn 159, Issue 4, 1998, Pages 1243-1246

  Gerber, Glenn S ^a   Gornik, Heather L ^a   Goldfischer, Evan R ^a   Chodak, Gerald W ^a   Rukstalis, Daniel B ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Prostate; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CLINICAL ARTICLE; CONSERVATIVE TREATMENT; DIAGNOSTIC VALUE; FOLLOW UP; HUMAN; HUMAN TISSUE; MALE; OBSERVATION; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0031940104     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)63572-9     Document Type: Article

References (13)

1. Oesterling, J. E.: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol., 145: 907, 1991.
2. Carter, H. B., Pearson, J. D., Metter, J., Brant, L. J., Chan, D. W., Andres, R., Fozard, J. L. and Walsh, P. C.: Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. J.A.M.A., 267: 2215, 1992.
3. Schmid, H. P., McNeal, J. E. and Stamey, T. A.: Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer, 71: 2031, 1993.
4. Carter, H. B. and Pearson, J. D.: Evaluation of changes in PSA in the management of men with prostate cancer. Sem. Oncol., 21: 554, 1994.
5. Chodak, G. W., Thisted, R. A., Gerber, G. S., Johansson, J. E., Adolfsson, J., Jones, G. W., Chisholm, G. D., Moskovitz, B., Livne, P. M. and Warner, J.: Results of conservative management of clinically localized prostate cancer. New Engl. J. Med., 330: 242, 1994.
6. Johansson, J. E., Holmberg, L., Johansson, S., Bergstrom, R. and Adami, H. O.: Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. J.A.M.A., 277: 467, 1997.
7. McNeal, J. E.: Origin and development of carcinoma in the prostate. Cancer, 23: 24, 1969.
8. Stamey, T. A., Kabalin, J. N., McNeal, J. E., Johnstone, I. M., Freiha, F., Redwine, E. A. and Yang, N.: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J. Urol., 141: 1076, 1989.
9. D'Amico, A. V. and Hanks, G. E.: Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer, 72: 2638, 1993.
10. Partin, A. W., Pearson, J. D., Landis, P. K., Carter, H. B., Pound, C. R., Clemens, J. Q., Epstein, J. I. and Walsh, P. C.: Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology, 43: 649, 1994.
11. Akimoto, S., Masai, M., Akakura, K. and Shimazaki, J.: Tumor marker doubling time in patients with prostate cancer: determination of prostate-specific antigen and prostatic acid phosphatase doubling time. Eur. Urol., 27: 207, 1995.
12. Steele, G. D., Osteen, R. T., Winchester, D. P., Murphy, G. P. and Menck, H. R.: Clinical highlights from the National Cancer Data Base: 1994. CA, 44: 71, 1994.
13. Carter, H. B., Morrell, C. H. and Pearson, J. D.: Estimation of prostatic growth using serial prostate specific antigen measurements in men with and without prostate disease. Cancer Res., 52: 3323, 1992.